Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рекомендации Маастрихт V/Флорентийского консенсуса по лечению хеликобактерной инфекции
Рекомендации Маастрихт V/Флорентийского консенсуса по лечению хеликобактерной инфекции
Пиманов С.И., Макаренко Е.В. Рекомендации Маастрихт V/Флорентийского консенсуса по лечению хеликобактерной инфекции. Consilium Medicum. 2017; 19 (8.1. Гастроэнтерология): 8–27.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель работы – анализ посвященного лечению инфекции Helicobacter pylori (H.pylori) раздела Маастрихт-V-Флорентийского консенсуса. Резистентность H. pylori к антибиотикам растет в большинстве регионов мира. Для некоторых эрадикационных протоколов уровень эрадикации может быть предопределен, если известна как частота эрадикации для чувствительных и резистентных штаммов, так и распространенность резистентности в популяции. Для оценки индивидуальной антибиотикорезистентности конкретного пациента следует учитывать применение им ключевых антибиотиков в анамнезе, а не только низкий уровень резистентности к этим антибиотикам в популяции. Оценка результатов чувствительности должна основываться как на популяционных, так и на индивидуальных данных. В регионах с высокой (>15%) резистентностью к кларитромицину рекомендуется квадротерапия с висмутом или без висмута, а также сопутствующая терапия (ингибитор протонной помпы – ИПП, амоксициллин, кларитромицин и нитроимидазол). В регионах с высокой резистентностью к кларитромицину и метронидазолу одновременно висмутсодержащая квадротерапия рекомендуется в качестве терапии первой линии. Продолжительность эрадикационной квадротерапии с висмутом должна быть удлинена до 14 дней, хотя для отдельных регионов доказана эффективность 10-дневной терапии. Продолжительность эрадикационной тройной терапии с кларитромицином должна быть удлинена до 14 дней. В регионах с низкой резистентностью к кларитромицину стандартная ИПП-кларитромицин-содержащая тройная терапия рекомендуется в качестве эмпирической терапии первой линии. Висмутсодержащая квадротерапия является альтернативой. Использование высоких доз ИПП дважды в день повышает эффективность тройной терапии. Эзомепразол и рабепразол могут быть предпочтительны в Европе и Северной Америке, где распространенность экстенсивных метаболизаторов ИПП высокая. После безуспешности висмутсодержащей квадротерапии может быть рекомендована фторхинолонсодержащая тройная или квадротерапия. В случаях высокой резистентности к хинолонам оптимальной может быть комбинация висмута с другими антибиотиками или рифабутином. В целом при сравнении с предыдущим консенсусом для лечения хеликобактерной инфекции предлагается более агрессивная антибиотикотерапия.
Ключевые слова: инфекция Helicobacter pylori, резистентность Helicobacter pylori к антибиотикам, ингибиторы протонной помпы, кларитромицин, амоксициллин, метронидазол, висмутсодержащая квадротерапия, метаанализ.
Key words: Helicobacter pylori infection, Helicobacter pylori antibiotic resistance, proton pump inhibitor, clarithromycin, amoxicillin, metronidazole, bismuth-containing quadruple therapy, meta-analysis.
Ключевые слова: инфекция Helicobacter pylori, резистентность Helicobacter pylori к антибиотикам, ингибиторы протонной помпы, кларитромицин, амоксициллин, метронидазол, висмутсодержащая квадротерапия, метаанализ.
________________________________________________
Key words: Helicobacter pylori infection, Helicobacter pylori antibiotic resistance, proton pump inhibitor, clarithromycin, amoxicillin, metronidazole, bismuth-containing quadruple therapy, meta-analysis.
Полный текст
Список литературы
1. Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167–80.
2. Malfertheiner P, Megraud F, O’Morain CA et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht III Consensus Report. Gut 2007; 56: 772–81.
3. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
4. Malfertheiner P, Megraud F, O'Morain C et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
5. Sugano К, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
6. Zagari RM, Romano M, Ojetti V et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015; 47: 903–12.
7. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151 (1): 51–69.
8. Graham D, Laine L. Toronto H. pylori Consensus Recommendations in Context. Gastroenterology 2016; 151 (1): 9–12.
9. Thung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–33.
10. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
11. Пиманов С.И., Макаренко Е.В. Анализ эффективности протоколов эрадикации инфекций Helicobacter pylori. Рецепт. 2005; 1: 19–23. / Pimanov S.I., Makarenko E.V. Analiz effektivnosti protokolov eradikatsii infektsii Helicobacter pylori. Retsept. 2005; 1: 19–23. [in Russian]
12. Federico A, Nardone G, Gravina AG et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55–61.e1; quiz e13–14.
13. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33–8.
14. Ince AT, Tozlu M, Baysal B et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepatogastroenterology 2014; 61: 1454–8.
15. Romano M, Fernandez-Bermejo M, Gravina AG et al. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 2013: 145 (1): 121–8.
16. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647–50.
17. Liu WZ, Xie Y, Cheng H et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013; 14: 211–21.
18. Liang X, Xu X, Zheng Q et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11: 802–7.
19. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343–57.
20. Lee BH, Kim N, Hwang TJ et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38–45.
21. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205–13.
22. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
23. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23: e880–93.
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177–86.
25. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703–10.
26. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30: 1338–45.
27. Wang B, Wang YH, Lv ZF et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79–88.
28. Sardarian H, Fakheri H, Hosseini V et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129–34.
29. De Francesco V, Hassan C, Ridola L et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63 (Pt 5): 748–52.
30. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338–47.
31. McNicholl A, Molina-Infante J, Bermejo F et al. Non-bismuth quadruple concomitant therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. Helicobacter 2014; 19: 11.
32. Gisbert JP, Molina-Infante J, Harb Y et al. Nonbismuth quadruple (concomitant) therapy for eradication of H. pylori: standard vs. optimized (14-day, high-dose PPI) regimen (abstr Su1172). Gastroenterology 2014; 146: S394–S395.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581–9.
34. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 68–77.
35. Makarenka AV, Pimanov SI. Eradicftion Rate After Randomized Treatment in a Population with High Prevalence of Helicobacter pylori Infection. Helicobacter 2005; 10: 535.
36. Пиманов С.И., Макаренко Е.В., Овчинников В.В. и др. Эрадикация инфекции Helicobacter pylori при использовании тройной терапии первого выбора. Мед. панорама. 2008; 88 (5): 46–8. / Pimanov S.I., Makarenko E.V., Ovchinnikov V.V. i dr. Eradikatsiia infektsii Helicobacter pylori pri ispol'zovanii troinoi terapii pervogo vybora. Med. panorama. 2008; 88 (5): 46–8. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414–25.
38. Wong AYS, Root A, Douglas IJ et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926.
39. Cheng Y-J, Nie X-Y, Chen X-M. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015; 66: 2173–84.
40. Gatta L, Zullo A, Perna F et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45–9.
41. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469–74.
42. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
43. Kang KK, Lee DH, Oh DH et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20: 6932–8.
44. Liu KSH, Hung IFN, Seto WKW et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410–5.
45. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35–44.
46. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488–96.
47. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
48. Di Caro S, Fini L, Daoud Y et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18: 5669–78.
49. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
50. Gisbert JP, Romano M, Gravina AG et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768–75.
51. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–8.
52. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
53. Moon JY, Kim GH, You HS et al. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013; 7 (4): 406–10.
54. Lee S, Lee DH, Lim JH. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and Gut Liver 2015; 9 (4): 478–85.
55. Matsumoto Y, Miki I, Aoyama N et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821–5.
56. Hu TH, Chuah SK, Hsu PI et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011; 342: 177–81.
57. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
58. Bago P, Vcev A, Tomic M et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372–8.
59. Gao X-Z, Qiao X-L, Song W-C, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357–62.
60. Yee YK, Cheung TK, Chu KM et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007; 26: 1063–7.
61. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450–6.
62. Cosme A, Lizasoan J, Montes M et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter 2016; 21: 29–34.
63. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905–13.
64. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562–7.
65. O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415–20.
66. Горгун Ю.В., Мараховский Ю.Х., Пиманов С.И. и др. Диагностика и лечение пациентов с заболеваниями органов пищеварения: клинический протокол. Минск: Профессиональные издания, 2016. / Gorgun Iu.V., Marakhovskii Iu.Kh., Pimanov S.I. i dr. Diagnostika i lechenie patsientov s zabolevaniiami organov pishchevareniia: klinicheskii protokol. Minsk: Professional'nye izdaniia, 2016. [in Russian]
67. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209–21.
68. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
69. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134–40.
70. Lv NH, Xie Y, Guo XB et al. Eradication therapy for Helicobacter pylori infection in patients with duodenal ulcers based on furazolidone triple therapy and quadruple therapy: a multicenter, randomized, control trial. Helicobacter 2011; 10 (Suppl. 1): 87.
71. Liang X, Xu X, Zheng Q et al. Efficacy of bismuthcontaining quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11 (7): 802–7.
72. Fakheri H, Merat S, Hosseini V et al. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19 (1): 89–93.
73. Исаева Г.Ш. Резистентность H. pylori к антибактериальным препаратам и методы ее определения. Клин. микробиология и антимикробная химиотерапия. 2010; 12 (1): 57–66. / Isaeva G.Sh. Rezistentnost' H. pylori k antibakterial'nym preparatam i metody ee opredeleniia. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 12 (1): 57–66. [in Russian]
74. Воропаева А.В., Воропаев Е.В., Баранов О.Ю. и др. Молекулярно-генетическое тестирование мутаций гена 23S рРНК Helicobacter pylori, определяющих резистентность к кларитромицину в Беларуси. Медико-биологические проблемы жизнедеятельности. 2010; 1 (3): 30–5. / Voropaeva A.V., Voropaev E.V., Baranov O.Iu. i dr. Molekuliarno-geneticheskoe testirovanie mutatsii gena 23S rRNK Helicobacter pylori, opredeliaiushchikh rezistentnost' k klaritromitsinu v Belarusi. Mediko-biologicheskie problemy zhiznedeiatel'nosti. 2010; 1 (3): 30–5. [in Russian]
75. Янович О.О., Носова Е.С., Титов Л.П., Дорошко М.В. Оценка резистентности Helicobacter pylori к кларитромицину методом ПЦР у больных хеликобактериозом. Здравоохранение. 2011; 12: 9–12. / Ianovich O.O., Nosova E.S., Titov L.P., Doroshko M.V. Otsenka rezistentnosti Helicobacter pylori k klaritromitsinu metodom PTsR u bol'nykh khelikobakteriozom. Zdravookhranenie. 2011; 12: 9–12. [in Russian]
2. Malfertheiner P, Megraud F, O’Morain CA et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht III Consensus Report. Gut 2007; 56: 772–81.
3. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
4. Malfertheiner P, Megraud F, O'Morain C et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
5. Sugano К, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
6. Zagari RM, Romano M, Ojetti V et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015; 47: 903–12.
7. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151 (1): 51–69.
8. Graham D, Laine L. Toronto H. pylori Consensus Recommendations in Context. Gastroenterology 2016; 151 (1): 9–12.
9. Thung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–33.
10. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
11. Pimanov S.I., Makarenko E.V. Analiz effektivnosti protokolov eradikatsii infektsii Helicobacter pylori. Retsept. 2005; 1: 19–23. [in Russian]
12. Federico A, Nardone G, Gravina AG et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55–61.e1; quiz e13–14.
13. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33–8.
14. Ince AT, Tozlu M, Baysal B et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepatogastroenterology 2014; 61: 1454–8.
15. Romano M, Fernandez-Bermejo M, Gravina AG et al. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 2013: 145 (1): 121–8.
16. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647–50.
17. Liu WZ, Xie Y, Cheng H et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013; 14: 211–21.
18. Liang X, Xu X, Zheng Q et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11: 802–7.
19. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343–57.
20. Lee BH, Kim N, Hwang TJ et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38–45.
21. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205–13.
22. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
23. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23: e880–93.
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177–86.
25. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703–10.
26. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30: 1338–45.
27. Wang B, Wang YH, Lv ZF et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79–88.
28. Sardarian H, Fakheri H, Hosseini V et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129–34.
29. De Francesco V, Hassan C, Ridola L et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63 (Pt 5): 748–52.
30. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338–47.
31. McNicholl A, Molina-Infante J, Bermejo F et al. Non-bismuth quadruple concomitant therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. Helicobacter 2014; 19: 11.
32. Gisbert JP, Molina-Infante J, Harb Y et al. Nonbismuth quadruple (concomitant) therapy for eradication of H. pylori: standard vs. optimized (14-day, high-dose PPI) regimen (abstr Su1172). Gastroenterology 2014; 146: S394–S395.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581–9.
34. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 68–77.
35. Makarenka AV, Pimanov SI. Eradicftion Rate After Randomized Treatment in a Population with High Prevalence of Helicobacter pylori Infection. Helicobacter 2005; 10: 535.
36. Pimanov S.I., Makarenko E.V., Ovchinnikov V.V. i dr. Eradikatsiia infektsii Helicobacter pylori pri ispol'zovanii troinoi terapii pervogo vybora. Med. panorama. 2008; 88 (5): 46–8. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414–25.
38. Wong AYS, Root A, Douglas IJ et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926.
39. Cheng Y-J, Nie X-Y, Chen X-M. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015; 66: 2173–84.
40. Gatta L, Zullo A, Perna F et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45–9.
41. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469–74.
42. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
43. Kang KK, Lee DH, Oh DH et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20: 6932–8.
44. Liu KSH, Hung IFN, Seto WKW et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410–5.
45. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35–44.
46. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488–96.
47. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
48. Di Caro S, Fini L, Daoud Y et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18: 5669–78.
49. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
50. Gisbert JP, Romano M, Gravina AG et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768–75.
51. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–8.
52. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
53. Moon JY, Kim GH, You HS et al. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013; 7 (4): 406–10.
54. Lee S, Lee DH, Lim JH. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and Gut Liver 2015; 9 (4): 478–85.
55. Matsumoto Y, Miki I, Aoyama N et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821–5.
56. Hu TH, Chuah SK, Hsu PI et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011; 342: 177–81.
57. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
58. Bago P, Vcev A, Tomic M et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372–8.
59. Gao X-Z, Qiao X-L, Song W-C, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357–62.
60. Yee YK, Cheung TK, Chu KM et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007; 26: 1063–7.
61. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450–6.
62. Cosme A, Lizasoan J, Montes M et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter 2016; 21: 29–34.
63. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905–13.
64. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562–7.
65. O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415–20.
66. Gorgun Iu.V., Marakhovskii Iu.Kh., Pimanov S.I. i dr. Diagnostika i lechenie patsientov s zabolevaniiami organov pishchevareniia: klinicheskii protokol. Minsk: Professional'nye izdaniia, 2016. [in Russian]
67. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209–21.
68. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
69. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134–40.
70. Lv NH, Xie Y, Guo XB et al. Eradication therapy for Helicobacter pylori infection in patients with duodenal ulcers based on furazolidone triple therapy and quadruple therapy: a multicenter, randomized, control trial. Helicobacter 2011; 10 (Suppl. 1): 87.
71. Liang X, Xu X, Zheng Q et al. Efficacy of bismuthcontaining quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11 (7): 802–7.
72. Fakheri H, Merat S, Hosseini V et al. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19 (1): 89–93.
73. Isaeva G.Sh. Rezistentnost' H. pylori k antibakterial'nym preparatam i metody ee opredeleniia. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 12 (1): 57–66. [in Russian]
74. Voropaeva A.V., Voropaev E.V., Baranov O.Iu. i dr. Molekuliarno-geneticheskoe testirovanie mutatsii gena 23S rRNK Helicobacter pylori, opredeliaiushchikh rezistentnost' k klaritromitsinu v Belarusi. Mediko-biologicheskie problemy zhiznedeiatel'nosti. 2010; 1 (3): 30–5. [in Russian]
75. Ianovich O.O., Nosova E.S., Titov L.P., Doroshko M.V. Otsenka rezistentnosti Helicobacter pylori k klaritromitsinu metodom PTsR u bol'nykh khelikobakteriozom. Zdravookhranenie. 2011; 12: 9–12. [in Russian]
2. Malfertheiner P, Megraud F, O’Morain CA et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht III Consensus Report. Gut 2007; 56: 772–81.
3. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
4. Malfertheiner P, Megraud F, O'Morain C et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
5. Sugano К, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
6. Zagari RM, Romano M, Ojetti V et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015; 47: 903–12.
7. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151 (1): 51–69.
8. Graham D, Laine L. Toronto H. pylori Consensus Recommendations in Context. Gastroenterology 2016; 151 (1): 9–12.
9. Thung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–33.
10. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
11. Пиманов С.И., Макаренко Е.В. Анализ эффективности протоколов эрадикации инфекций Helicobacter pylori. Рецепт. 2005; 1: 19–23. / Pimanov S.I., Makarenko E.V. Analiz effektivnosti protokolov eradikatsii infektsii Helicobacter pylori. Retsept. 2005; 1: 19–23. [in Russian]
12. Federico A, Nardone G, Gravina AG et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55–61.e1; quiz e13–14.
13. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33–8.
14. Ince AT, Tozlu M, Baysal B et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepatogastroenterology 2014; 61: 1454–8.
15. Romano M, Fernandez-Bermejo M, Gravina AG et al. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 2013: 145 (1): 121–8.
16. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647–50.
17. Liu WZ, Xie Y, Cheng H et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013; 14: 211–21.
18. Liang X, Xu X, Zheng Q et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11: 802–7.
19. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343–57.
20. Lee BH, Kim N, Hwang TJ et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38–45.
21. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205–13.
22. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
23. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23: e880–93.
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177–86.
25. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703–10.
26. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30: 1338–45.
27. Wang B, Wang YH, Lv ZF et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79–88.
28. Sardarian H, Fakheri H, Hosseini V et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129–34.
29. De Francesco V, Hassan C, Ridola L et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63 (Pt 5): 748–52.
30. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338–47.
31. McNicholl A, Molina-Infante J, Bermejo F et al. Non-bismuth quadruple concomitant therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. Helicobacter 2014; 19: 11.
32. Gisbert JP, Molina-Infante J, Harb Y et al. Nonbismuth quadruple (concomitant) therapy for eradication of H. pylori: standard vs. optimized (14-day, high-dose PPI) regimen (abstr Su1172). Gastroenterology 2014; 146: S394–S395.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581–9.
34. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 68–77.
35. Makarenka AV, Pimanov SI. Eradicftion Rate After Randomized Treatment in a Population with High Prevalence of Helicobacter pylori Infection. Helicobacter 2005; 10: 535.
36. Пиманов С.И., Макаренко Е.В., Овчинников В.В. и др. Эрадикация инфекции Helicobacter pylori при использовании тройной терапии первого выбора. Мед. панорама. 2008; 88 (5): 46–8. / Pimanov S.I., Makarenko E.V., Ovchinnikov V.V. i dr. Eradikatsiia infektsii Helicobacter pylori pri ispol'zovanii troinoi terapii pervogo vybora. Med. panorama. 2008; 88 (5): 46–8. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414–25.
38. Wong AYS, Root A, Douglas IJ et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926.
39. Cheng Y-J, Nie X-Y, Chen X-M. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015; 66: 2173–84.
40. Gatta L, Zullo A, Perna F et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45–9.
41. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469–74.
42. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
43. Kang KK, Lee DH, Oh DH et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20: 6932–8.
44. Liu KSH, Hung IFN, Seto WKW et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410–5.
45. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35–44.
46. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488–96.
47. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
48. Di Caro S, Fini L, Daoud Y et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18: 5669–78.
49. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
50. Gisbert JP, Romano M, Gravina AG et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768–75.
51. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–8.
52. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
53. Moon JY, Kim GH, You HS et al. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013; 7 (4): 406–10.
54. Lee S, Lee DH, Lim JH. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and Gut Liver 2015; 9 (4): 478–85.
55. Matsumoto Y, Miki I, Aoyama N et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821–5.
56. Hu TH, Chuah SK, Hsu PI et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011; 342: 177–81.
57. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
58. Bago P, Vcev A, Tomic M et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372–8.
59. Gao X-Z, Qiao X-L, Song W-C, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357–62.
60. Yee YK, Cheung TK, Chu KM et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007; 26: 1063–7.
61. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450–6.
62. Cosme A, Lizasoan J, Montes M et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter 2016; 21: 29–34.
63. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905–13.
64. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562–7.
65. O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415–20.
66. Горгун Ю.В., Мараховский Ю.Х., Пиманов С.И. и др. Диагностика и лечение пациентов с заболеваниями органов пищеварения: клинический протокол. Минск: Профессиональные издания, 2016. / Gorgun Iu.V., Marakhovskii Iu.Kh., Pimanov S.I. i dr. Diagnostika i lechenie patsientov s zabolevaniiami organov pishchevareniia: klinicheskii protokol. Minsk: Professional'nye izdaniia, 2016. [in Russian]
67. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209–21.
68. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
69. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134–40.
70. Lv NH, Xie Y, Guo XB et al. Eradication therapy for Helicobacter pylori infection in patients with duodenal ulcers based on furazolidone triple therapy and quadruple therapy: a multicenter, randomized, control trial. Helicobacter 2011; 10 (Suppl. 1): 87.
71. Liang X, Xu X, Zheng Q et al. Efficacy of bismuthcontaining quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11 (7): 802–7.
72. Fakheri H, Merat S, Hosseini V et al. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19 (1): 89–93.
73. Исаева Г.Ш. Резистентность H. pylori к антибактериальным препаратам и методы ее определения. Клин. микробиология и антимикробная химиотерапия. 2010; 12 (1): 57–66. / Isaeva G.Sh. Rezistentnost' H. pylori k antibakterial'nym preparatam i metody ee opredeleniia. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 12 (1): 57–66. [in Russian]
74. Воропаева А.В., Воропаев Е.В., Баранов О.Ю. и др. Молекулярно-генетическое тестирование мутаций гена 23S рРНК Helicobacter pylori, определяющих резистентность к кларитромицину в Беларуси. Медико-биологические проблемы жизнедеятельности. 2010; 1 (3): 30–5. / Voropaeva A.V., Voropaev E.V., Baranov O.Iu. i dr. Molekuliarno-geneticheskoe testirovanie mutatsii gena 23S rRNK Helicobacter pylori, opredeliaiushchikh rezistentnost' k klaritromitsinu v Belarusi. Mediko-biologicheskie problemy zhiznedeiatel'nosti. 2010; 1 (3): 30–5. [in Russian]
75. Янович О.О., Носова Е.С., Титов Л.П., Дорошко М.В. Оценка резистентности Helicobacter pylori к кларитромицину методом ПЦР у больных хеликобактериозом. Здравоохранение. 2011; 12: 9–12. / Ianovich O.O., Nosova E.S., Titov L.P., Doroshko M.V. Otsenka rezistentnosti Helicobacter pylori k klaritromitsinu metodom PTsR u bol'nykh khelikobakteriozom. Zdravookhranenie. 2011; 12: 9–12. [in Russian]
________________________________________________
2. Malfertheiner P, Megraud F, O’Morain CA et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht III Consensus Report. Gut 2007; 56: 772–81.
3. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
4. Malfertheiner P, Megraud F, O'Morain C et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
5. Sugano К, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
6. Zagari RM, Romano M, Ojetti V et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015; 47: 903–12.
7. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151 (1): 51–69.
8. Graham D, Laine L. Toronto H. pylori Consensus Recommendations in Context. Gastroenterology 2016; 151 (1): 9–12.
9. Thung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–33.
10. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
11. Pimanov S.I., Makarenko E.V. Analiz effektivnosti protokolov eradikatsii infektsii Helicobacter pylori. Retsept. 2005; 1: 19–23. [in Russian]
12. Federico A, Nardone G, Gravina AG et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55–61.e1; quiz e13–14.
13. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33–8.
14. Ince AT, Tozlu M, Baysal B et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepatogastroenterology 2014; 61: 1454–8.
15. Romano M, Fernandez-Bermejo M, Gravina AG et al. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 2013: 145 (1): 121–8.
16. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647–50.
17. Liu WZ, Xie Y, Cheng H et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013; 14: 211–21.
18. Liang X, Xu X, Zheng Q et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11: 802–7.
19. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343–57.
20. Lee BH, Kim N, Hwang TJ et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38–45.
21. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205–13.
22. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
23. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23: e880–93.
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177–86.
25. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703–10.
26. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30: 1338–45.
27. Wang B, Wang YH, Lv ZF et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79–88.
28. Sardarian H, Fakheri H, Hosseini V et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129–34.
29. De Francesco V, Hassan C, Ridola L et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63 (Pt 5): 748–52.
30. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338–47.
31. McNicholl A, Molina-Infante J, Bermejo F et al. Non-bismuth quadruple concomitant therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. Helicobacter 2014; 19: 11.
32. Gisbert JP, Molina-Infante J, Harb Y et al. Nonbismuth quadruple (concomitant) therapy for eradication of H. pylori: standard vs. optimized (14-day, high-dose PPI) regimen (abstr Su1172). Gastroenterology 2014; 146: S394–S395.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581–9.
34. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 68–77.
35. Makarenka AV, Pimanov SI. Eradicftion Rate After Randomized Treatment in a Population with High Prevalence of Helicobacter pylori Infection. Helicobacter 2005; 10: 535.
36. Pimanov S.I., Makarenko E.V., Ovchinnikov V.V. i dr. Eradikatsiia infektsii Helicobacter pylori pri ispol'zovanii troinoi terapii pervogo vybora. Med. panorama. 2008; 88 (5): 46–8. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414–25.
38. Wong AYS, Root A, Douglas IJ et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926.
39. Cheng Y-J, Nie X-Y, Chen X-M. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015; 66: 2173–84.
40. Gatta L, Zullo A, Perna F et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45–9.
41. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469–74.
42. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
43. Kang KK, Lee DH, Oh DH et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20: 6932–8.
44. Liu KSH, Hung IFN, Seto WKW et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410–5.
45. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35–44.
46. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488–96.
47. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
48. Di Caro S, Fini L, Daoud Y et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18: 5669–78.
49. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
50. Gisbert JP, Romano M, Gravina AG et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768–75.
51. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–8.
52. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843–61.
53. Moon JY, Kim GH, You HS et al. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013; 7 (4): 406–10.
54. Lee S, Lee DH, Lim JH. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and Gut Liver 2015; 9 (4): 478–85.
55. Matsumoto Y, Miki I, Aoyama N et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821–5.
56. Hu TH, Chuah SK, Hsu PI et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011; 342: 177–81.
57. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
58. Bago P, Vcev A, Tomic M et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372–8.
59. Gao X-Z, Qiao X-L, Song W-C, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357–62.
60. Yee YK, Cheung TK, Chu KM et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007; 26: 1063–7.
61. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450–6.
62. Cosme A, Lizasoan J, Montes M et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter 2016; 21: 29–34.
63. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905–13.
64. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562–7.
65. O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415–20.
66. Gorgun Iu.V., Marakhovskii Iu.Kh., Pimanov S.I. i dr. Diagnostika i lechenie patsientov s zabolevaniiami organov pishchevareniia: klinicheskii protokol. Minsk: Professional'nye izdaniia, 2016. [in Russian]
67. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209–21.
68. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
69. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134–40.
70. Lv NH, Xie Y, Guo XB et al. Eradication therapy for Helicobacter pylori infection in patients with duodenal ulcers based on furazolidone triple therapy and quadruple therapy: a multicenter, randomized, control trial. Helicobacter 2011; 10 (Suppl. 1): 87.
71. Liang X, Xu X, Zheng Q et al. Efficacy of bismuthcontaining quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11 (7): 802–7.
72. Fakheri H, Merat S, Hosseini V et al. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19 (1): 89–93.
73. Isaeva G.Sh. Rezistentnost' H. pylori k antibakterial'nym preparatam i metody ee opredeleniia. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 12 (1): 57–66. [in Russian]
74. Voropaeva A.V., Voropaev E.V., Baranov O.Iu. i dr. Molekuliarno-geneticheskoe testirovanie mutatsii gena 23S rRNK Helicobacter pylori, opredeliaiushchikh rezistentnost' k klaritromitsinu v Belarusi. Mediko-biologicheskie problemy zhiznedeiatel'nosti. 2010; 1 (3): 30–5. [in Russian]
75. Ianovich O.O., Nosova E.S., Titov L.P., Doroshko M.V. Otsenka rezistentnosti Helicobacter pylori k klaritromitsinu metodom PTsR u bol'nykh khelikobakteriozom. Zdravookhranenie. 2011; 12: 9–12. [in Russian]
Авторы
С.И.Пиманов*, Е.В.Макаренко
УО «Витебский государственный ордена Дружбы народов медицинский университет». 210023, Республика Беларусь, Витебск, пр-т Фрунзе, д. 27
*pimanovs@tut.by
Vitebsk State Order of Peoples' Friendship Medical University. 210023, Republic of Belarus, Vitebsk, pr-t Frunze, d. 27
*pimanovs@tut.by
УО «Витебский государственный ордена Дружбы народов медицинский университет». 210023, Республика Беларусь, Витебск, пр-т Фрунзе, д. 27
*pimanovs@tut.by
________________________________________________
Vitebsk State Order of Peoples' Friendship Medical University. 210023, Republic of Belarus, Vitebsk, pr-t Frunze, d. 27
*pimanovs@tut.by
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.